Chair: Dr Dermot Neely // Co-chair: Dr Jaimini Cegla

Chair: Dr Handrean Soran // Co-chair: Dr Dev Datta

Dr Dermot Neely is former Head of the Lipid Clinic, Royal Victoria Infirmary, Newcastle and Director of Supra-Regional Assay Services for Lipids and Cardiovascular Biomarkers in the Integrated Laboratory Medicine Directorate, Newcastle upon Tyne Hospitals NHS Foundation Trust. He was an expert adviser on the NICE Lipid Modification Guidelines in 2008 (CG67) and member of the Guideline Development Group for the CG181 guideline in 2012-14.

Now retired from clinical practice, he is currently Specialist Adviser on Lipids to the Academic Health Sciences Network for North East and North Cumbria, a member of the AAC Rapid Uptake Products Working Group on PCSK9 inhibitors and sits on the NHSE Specialist Advisory Group on Familial Hypercholesterolaemia. Dr Neely is a founder Trustee of HEART UK and co-chair of the HEART UK Familial Hypercholesterolaemia Intelligence Network (FHIN).

Dr Handrean Soran is Consultant Physician and Endocrinologist & Honorary Senior Lecturer at Manchester University Hospitals NHS Foundation Trust. He has a specialist interest in lipidology, atherosclerosis, cardiovascular risk, parathyroid, calcium and bone metabolism. He provides a tertiary centre service for lipoprotein disorders, as well as calcium and metabolic bone diseases.

Dr Soran is the Chair of HEART UK’s Medical, Scientific and Research Committee, co-chair of the National Familial Hypercholesterolaemia task force in the UK, a member of the UK lipoprotein apheresis committee and European Atherosclerosis Society’s Familial Hypercholesterolaemia Collaborative Study (FHSC) executive committee. He served as the President of the Lipid, Metabolism and Vascular Section of the Royal Society of Medicine and remains a member of the section’s council.

Dr Jaimini Cegla completed internal medicine training in the UK and Australia, and trained in metabolic medicine at Imperial College Trust and Guy’s and St Thomas’. She has a specialist interest in lipidology and cardiovascular risk. The Hammersmith Hospital lipid service is a one-stop centre for the genetic diagnosis and management of lipid disorders and also offers research facilities and access to new medications.

Dr Cegla’s current research focuses on cardiovascular risk including clinical trials of novel therapeutic agents. Dr Cegla is a member of the Medical, Scientific and Research Committee of HEART UK, the cholesterol charity. She also sits on the National Cardiovascular Disease Prevention System Leadership Forum, the advisory group of Public Health England for strategy on CVD prevention.

Dr Dev Datta completed medical school in Cardiff, then trained in cardiology and general medicine in Wales and Edinburgh. During this period he was awarded a BHF junior research fellowship at Cardiff University and was subsequently awarded his MD. Having developed an interest in preventative cardiology and vascular medicine, he then completed training in medical biochemistry and metabolic medicine in Cardiff. He was appointed as a consultant in 2011.

He is clinical lead for the lipoprotein apheresis service in Cardiff and is medical lead for FH Wales, the Welsh Familial Hypercholesterolaemia cascade testing service. He runs a clinical nutrition service addressing medical complications of eating disorders and is clinical lead for the specialist weight management service in Cardiff. His research interests are FH and vascular biology.